title: Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.
abstract: This study assessed the effect of GLP-1 based therapies on atherosclerotic markers in type 2 diabetes patients. 31 studies were selected to obtain data after multiple database searches and following inclusion and exclusion criteria. Age and BMI of the participants of longitudinal studies were 59.8 ± 8.3 years and 29.2 ± 5.7 kg/m(2) (Mean±SD). Average duration of GLP-1 based therapies was 20.5 weeks. Percent flow-mediated diameter (%FMD) did not change from baseline significantly but when compared to controls, %FMD increased non-significantly following GLP-1-based therapies (1.65 [-0.89, 4.18]; P = 0.2; REM) in longitudinal studies and increased significantly in cross sectional studies (2.58 [1.68, 3.53]; P < 0.00001). Intima media thickness decreased statistically non-significantly by the GLP-1 based therapies. GLP-1 based therapies led to statistically significant reductions in the serum levels of brain natriuretic peptide (-40.16 [-51.50, -28.81]; P < 0.0001; REM), high sensitivity c-reactive protein (-0.27 [-0.48, -0.07]; P = 0.009), plasminogen activator inhibitor-1 (-12.90 [-25.98, 0.18]; P=0.05), total cholesterol (-5.47 [-9.55, -1.39]; P = 0.009), LDL-cholesterol (-3.70 [-7.39, -0.00]; P = 0.05) and triglycerides (-16.44 [-25.64, -7.23]; P = 0.0005) when mean differences with 95% CI in the changes from baselines were meta-analyzed. In conclusion, GLP-1-based therapies appear to provide beneficial effects against atherosclerosis. More randomized data will be required to arrive at conclusive evidence.
authors.affiliation: 1] Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China [2] Department of Endocrinology, Chinese PLA 309 Hospital, Beijing 100091, China.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Song
authors.affiliation: Department of Endocrinology, Chinese PLA 309 Hospital, Beijing 100091, China.
authors.forename: Hetang
authors.initials: H
authors.lastname: Jia
authors.affiliation: Department of Acupuncture, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yuebo
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Orthopedics, Chinese PLA 309 Hospital, Beijing 100091.
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Orthopedics, Chinese PLA 309 Hospital, Beijing 100091.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yiming
authors.initials: Y
authors.lastname: Mu
authors.affiliation: Department of Geriatric Endocrinology, General Hospital of PLA, Beijing 100853, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D059168:Carotid Intima-Media Thickness; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D014280:Triglycerides / Q000097:blood
chemical_list: D008078:Cholesterol, LDL; D007004:Hypoglycemic Agents; D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides; D020097:Natriuretic Peptide, Brain; D052216:Glucagon-Like Peptide 1; D002097:C-Reactive Protein; D002784:Cholesterol